Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRESELIBET: BV-ESHAP versus ESHAP salvage therapy in relapsed or refractory classical Hodgkin lymphoma
MOH_2021-01-26_009531Phase 2Active, not recruiting
- Sponsor
- GELTAMO
- Start
- Jan 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by GELTAMO. Primary endpoint: Complete metabolic response rate. Started Jan 2021; status: active, not recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on MOH_2021-01-26_009531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-26_009531.